Synapse - Raza Hoda

Results (10)

Assessing PD-L1 expression status using radiomic features from contrast-enhanced breast MRI in breast cancer patients: Initial results

Journal Article

Lo Gullo, R.; Wen, H.; Reiner, J. S.; Hoda, R.; Sevilimedu, V.; Martinez, D. F.; Thakur, S. B.; Jochelson, M. S.; Gibbs, P.; Pinker, K.
Cancers (2021)

Fulltext@MSK | Save

Interobserver variation of PD-L1 SP142 immunohistochemistry interpretation in breast carcinoma: A study of 79 cases using whole slide imaging

Journal Article

Hoda, R. S.; Brogi, E.; D'Alfonso, T. M.; Grabenstetter, A.; Giri, D.; Hanna, M. G.; Kuba, M. G.; Murray, M. P.; Vallejo, C. E.; Zhang, H.; more...
Archives of Pathology & Laboratory Medicine (2021)

Fulltext@MSK | Save

PD-L1 expression in metaplastic breast carcinoma using the PD-L1 SP142 assay and concordance among PD-L1 immunohistochemical assays

Journal Article

Grabenstetter, A.; Jungbluth, A. A.; Frosina, D.; Hoda, R.; Dos Anjos, C. H.; Patil, S.; Sevilimedu, V.; Weigelt, B.; Reis-Filho, J. S.; Zhang, H.; more...
American Journal of Surgical Pathology (2021)

Fulltext@MSK | Save

Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: A focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline

Journal Article

Hoda, R. S.; Bowman, A. S.; Zehir, A.; Razavi, P.; Brogi, E.; Ladanyi, M.; Arcila, M. E.; Wen, H. Y.; Ross, D. S.
Histopathology (2021)

Fulltext@MSK | Save

Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma

Journal Article

Hoda, R. S.; Brogi, E.; Dos Anjos, C. H.; Grabenstetter, A.; Ventura, K.; Patil, S.; Selenica, P.; Weigelt, B.; Reis-Filho, J. S.; Traina, T.; more...
Modern Pathology (2020)

Fulltext@MSK | Save

Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 guideline updates on HER2 assessment in breast cancer with equivocal HER2 immunohistochemistry results with focus on cases with HER2/CEP17 ratio <2.0 and average HER2 copy number ≥4.0 and <6.0

Journal Article

Hoda, R. S.; Brogi, E.; Xu, J.; Ventura, K.; Ross, D. S.; Dang, C.; Robson, M.; Norton, L.; Morrow, M.; Wen, H. Y.
Archives of Pathology & Laboratory Medicine (2020)

Fulltext@MSK | Save

PD-L1 expression in metaplastic breast carcinoma (MBC) using PD-L1 SP142 assay and concordance among PD-L1 immunohistochemical (IHC) assays

Meeting Abstract

Grabenstetter, A.; Jungbluth, A.; Frosina, D.; Hoda, R.; Weigelt, B.; Reis-Filho, J.; Zhang, H.; Traina, T.; Robson, M.; Brogi, E.; more...
Laboratory Investigation (2020)

Fulltext@MSK | Save

Interobserver variation of PD-L1 (SP142) immunohistochemistry interpretation in breast carcinoma

Meeting Abstract

Hoda, R.; Brogi, E.; D'Alfonso, T.; Grabenstetter, A.; Giri, D.; Hanna, M.; Kuba, M. G.; Murray, M.; Vallejo, C.; Zhang, H.; more...
Laboratory Investigation (2020)

Fulltext@MSK | Save

Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) status in breast cancer: A focus on group 4 using the 2018 ASCO/CAP HER2 testing guideline